ACRIVON Trademark

Trademark Overview


On Thursday, September 11, 2025, a trademark application was filed for ACRIVON with the United States Patent and Trademark Office. The USPTO has given the ACRIVON trademark a serial number of 99388089. The federal status of this trademark filing is PUBLISHED FOR OPPOSITION as of Tuesday, March 3, 2026. This trademark is owned by Acrivon Therapeutics, Inc.. The ACRIVON trademark is filed in the Pharmaceutical Products, Computer & Software Services & Scientific Services, and Medical & Beauty Services & Agricultural Services categories with the following description:

Pharmaceutical preparations for the treatment and prevention of cancer, fibrotic, inflammatory, autoimmune, metabolic, infectious, and central nervous system diseases; Protein arrays for diagnosing cancer; Pharmaceutical preparations for the prediction of drug treatment efficacy; Diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; Diagnostic kits comprising diagnostic agents, preparations and substances for medical purposes; Reagents for medical purposes; Medical diagnostic reagents for use in drug-tailored efficacy predication and analysis; Diagnostic agents, preparations and substances for medical purposes; Diagnostic biomarker reagents for medical purposes; Diagnostic preparations for medical purposes; Diagnostic preparations for medical purposes for detecting genetic predispositions; Biological preparations for the prevention and treatment of cancer, fibrotic, inflammatory, autoimmune, metabolic, infectious, and central n...

Medical services; Medical testing services; Medical diagnostic testing, monitoring and reporting services; Medical testing services relating to the diagnosis and treatment of disease; Medical testing for diagnostic or treatment purposes in the field of oncology, fibrotic, inflammatory, autoimmune, metabolic, infectious, and central nervous system diseases; Medical counseling; Providing medical information to medical professional in the form of reports in the field of oncology and precision medicine; Providing a website featuring information in the field of oncology, fibrotic, inflammatory, autoimmune, metabolic, infectious, and central nervous system diseases and precision medicine health

Medical and scientific research in the field of oncology; Medical and scientific research in the field of proteomics, biomarker discovery, rational drug design in drug discovery, patient responder identification and indication finding, and precision medicine clinical trials based on responder identification; Biochemical analysis services in the field of biomarker discovery; Providing medical testing services and information in the field of cancer research and disease classification; Scientific research in the field of pharmaceuticals, therapeutics, and drug formulation and delivery; Scientific research in the field of proteomics and biomarker discovery; Consulting services in the field of pharmaceutical research and development; Pharmaceutical research services; Research and development in the pharmaceutical and biotechnology fields
acrivon

General Information


Serial Number99388089
Word MarkACRIVON
Filing DateThursday, September 11, 2025
Status686 - PUBLISHED FOR OPPOSITION
Status DateTuesday, March 3, 2026
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, March 3, 2026

Trademark Statements


Goods and ServicesPharmaceutical preparations for the treatment and prevention of cancer, fibrotic, inflammatory, autoimmune, metabolic, infectious, and central nervous system diseases; Protein arrays for diagnosing cancer; Pharmaceutical preparations for the prediction of drug treatment efficacy; Diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; Diagnostic kits comprising diagnostic agents, preparations and substances for medical purposes; Reagents for medical purposes; Medical diagnostic reagents for use in drug-tailored efficacy predication and analysis; Diagnostic agents, preparations and substances for medical purposes; Diagnostic biomarker reagents for medical purposes; Diagnostic preparations for medical purposes; Diagnostic preparations for medical purposes for detecting genetic predispositions; Biological preparations for the prevention and treatment of cancer, fibrotic, inflammatory, autoimmune, metabolic, infectious, and central nervous system diseases
Goods and ServicesMedical services; Medical testing services; Medical diagnostic testing, monitoring and reporting services; Medical testing services relating to the diagnosis and treatment of disease; Medical testing for diagnostic or treatment purposes in the field of oncology, fibrotic, inflammatory, autoimmune, metabolic, infectious, and central nervous system diseases; Medical counseling; Providing medical information to medical professional in the form of reports in the field of oncology and precision medicine; Providing a website featuring information in the field of oncology, fibrotic, inflammatory, autoimmune, metabolic, infectious, and central nervous system diseases and precision medicine health
Goods and ServicesMedical and scientific research in the field of oncology; Medical and scientific research in the field of proteomics, biomarker discovery, rational drug design in drug discovery, patient responder identification and indication finding, and precision medicine clinical trials based on responder identification; Biochemical analysis services in the field of biomarker discovery; Providing medical testing services and information in the field of cancer research and disease classification; Scientific research in the field of pharmaceuticals, therapeutics, and drug formulation and delivery; Scientific research in the field of proteomics and biomarker discovery; Consulting services in the field of pharmaceutical research and development; Pharmaceutical research services; Research and development in the pharmaceutical and biotechnology fields

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, September 11, 2025
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateThursday, September 11, 2025
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateThursday, September 11, 2025
Primary Code044
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameAcrivon Therapeutics, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressWatertown, MA 02472
US

Party NameAcrivon Therapeutics, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressWatertown, MA 02472
US

Trademark Events


Event DateEvent Description
Thursday, September 11, 2025NEW APPLICATION ENTERED
Thursday, September 11, 2025APPLICATION FILING RECEIPT MAILED
Tuesday, February 3, 2026NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Wednesday, February 4, 2026ASSIGNED TO EXAMINER
Thursday, February 5, 2026EXAMINERS AMENDMENT -WRITTEN
Thursday, February 5, 2026EXAMINERS AMENDMENT E-MAILED
Thursday, February 5, 2026NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Thursday, February 5, 2026EXAMINER'S AMENDMENT ENTERED
Thursday, February 5, 2026APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, February 25, 2026NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, March 3, 2026PUBLISHED FOR OPPOSITION
Tuesday, March 3, 2026OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED